Torsdag 26 December | 14:26:12 Europe / Stockholm

Kalender

Tid*
2025-11-06 N/A Kvartalsrapport 2025-Q3
2025-08-14 N/A Kvartalsrapport 2025-Q2
2025-05-27 N/A Årsstämma
2025-05-08 N/A Kvartalsrapport 2025-Q1
2025-02-13 N/A Bokslutskommuniké 2024
2024-11-06 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-06-26 - Årsstämma
2024-06-06 - X-dag ordinarie utdelning AZT 0.00 NOK
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-01 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-07 - X-dag ordinarie utdelning AZT 0.00 NOK
2023-06-06 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-02 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-06-23 - Årsstämma
2022-05-27 - X-dag ordinarie utdelning AZT 0.00 NOK
2022-04-28 - Kvartalsrapport 2022-Q1
2022-01-27 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning AZT 0.00 NOK
2021-05-20 - Årsstämma
2021-04-22 - Kvartalsrapport 2021-Q1
2021-01-28 - Bokslutskommuniké 2020
2020-10-22 - Kvartalsrapport 2020-Q3
2020-08-19 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning AZT 0.00 NOK
2020-05-14 - Årsstämma
2020-04-23 - Kvartalsrapport 2020-Q1
2020-01-30 - Bokslutskommuniké 2019
2020-01-06 - Extra Bolagsstämma 2020
2019-10-24 - Kvartalsrapport 2019-Q3
2019-08-15 - Kvartalsrapport 2019-Q2
2019-05-16 - X-dag ordinarie utdelning AZT 0.00 NOK
2019-05-15 - Årsstämma
2019-04-30 - Kvartalsrapport 2019-Q1
2019-01-30 - Bokslutskommuniké 2018
2018-10-18 - Kvartalsrapport 2018-Q3
2018-08-16 - Kvartalsrapport 2018-Q2
2018-05-09 - X-dag ordinarie utdelning AZT 0.00 NOK
2018-05-07 - Årsstämma
2018-04-26 - Kvartalsrapport 2018-Q1
2018-02-01 - Bokslutskommuniké 2017
2017-10-19 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2
2017-05-12 - X-dag ordinarie utdelning AZT 0.00 NOK
2017-05-11 - Årsstämma
2017-04-27 - Kvartalsrapport 2017-Q1
2017-02-02 - Bokslutskommuniké 2016
2016-10-26 - Kvartalsrapport 2016-Q3
2016-08-17 - Kvartalsrapport 2016-Q2
2016-05-12 - X-dag ordinarie utdelning AZT 0.00 NOK
2016-05-11 - Årsstämma
2016-04-19 - Kvartalsrapport 2016-Q1
2016-02-11 - Kapitalmarknadsdag 2016
2016-02-11 - Bokslutskommuniké 2015
2015-11-03 - Kvartalsrapport 2015-Q3
2015-08-13 - Kvartalsrapport 2015-Q2
2015-05-13 - X-dag ordinarie utdelning AZT 0.00 NOK
2015-05-12 - Årsstämma
2015-05-05 - Kvartalsrapport 2015-Q1
2015-02-17 - Bokslutskommuniké 2014
2014-11-05 - Kvartalsrapport 2014-Q3
2014-08-13 - Kvartalsrapport 2014-Q2
2014-05-15 - X-dag ordinarie utdelning AZT 0.00 NOK
2014-05-14 - Årsstämma
2014-04-30 - Kvartalsrapport 2014-Q1
2014-02-14 - Bokslutskommuniké 2013
2013-11-01 - Kvartalsrapport 2013-Q3
2013-08-09 - Kvartalsrapport 2013-Q2
2013-06-13 - Kapitalmarknadsdag 2013
2013-05-28 - X-dag ordinarie utdelning
2013-05-27 - Årsstämma
2013-05-07 - Kvartalsrapport 2013-Q1
2013-02-01 - Extra Bolagsstämma 2013
2013-01-07 - Bokslutskommuniké 2012
2012-11-06 - Kvartalsrapport 2012-Q3
2012-08-10 - Kvartalsrapport 2012-Q2
2012-05-07 - Årsstämma
2012-05-07 - Kvartalsrapport 2012-Q1
2012-05-07 - X-dag ordinarie utdelning AZT 0.00 NOK
2012-02-21 - Bokslutskommuniké 2011
2011-11-08 - Kvartalsrapport 2011-Q3
2011-08-10 - Kvartalsrapport 2011-Q2
2011-05-13 - Årsstämma
2011-05-13 - Kvartalsrapport 2011-Q1
2011-05-12 - X-dag ordinarie utdelning
2011-02-17 - Bokslutskommuniké 2010
2010-11-12 - Kvartalsrapport 2010-Q3
2010-08-10 - Kvartalsrapport 2010-Q2
2010-05-11 - Kvartalsrapport 2010-Q1
2010-05-04 - Årsstämma
2010-03-03 - Bokslutskommuniké 2009

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
ArcticZymes Technologies är verksamma inom bioteknik. Bolaget specialiserar sig inom forskning och utveckling av läkemedel för behandling av autoimmuna sjukdomar. Störst inriktning återfinns inom utveckling av glukaner, framtagande av immunstimulerande medel, samt analys av enzymer. Visionen är att testa och utveckla medicinen för att sedan föra vidare dessa i användning för RNA och DNA processer. Bolaget gick tidigare under namnet Biotec Pharmacon och har sitt huvudkontor i Tromsö.
2020-06-17 08:41:52
Tromsø, Norway, 17. June 2020 - Biotec Pharmacon (OSE: BIOTEC) announces it has
officially rebranded to ArcticZymes Technologies.

As previously announced and decided by the Annual General Meeting, Biotec
Pharmacon ASA has formally changed its name to ArcticZymes Technologies ASA. The
new name is formally registered with Brønnøysundregistrene and will trade under
the new ticker "AZT" over the next days.

The name change will also coincide with the unveiling of a new brand identity, a
new corporate logo and an updated website (Arcticzymes.com)

The company has undergone a significant transformation over the last year with
the ArcticZymes subsidiary representing the core business and profitable part of
the company. The new brand reflects the company's future identity and strategy
to focus on growing its enzymes business via a combination of organic and
inorganic initiatives. Longer-term, the company has ambitions to expand into
other technologies beyond enzymes.

ArcticZymes is a global leader in supplying best-in-class enzyme technologies to
commercial partners who develop therapeutics, In vitro Diagnostics (IVD) and
molecular research kit products. The success of the enzymes business has been a
result of forging long-term commercial partnerships with its customers as a
reliable and trusted supplier. Hence, incorporating ArcticZymes into the new
corporate brand name is instrumental in recognizing the strong and positive
brand positioning the company has achieved in the market.

The two subsidiaries, ArcticZymes AS and Biotec BetaGlucans AS will remain.
However, the future direction and activities of the group will be very different
than earlier with the enzyme business being at the forefront.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"ArcticZymes Technologies has arrived and the company enters a new era. Our
future is all about enzymes. With this, the company needed a new image and
identity that reflects its foundations and recognizes what is core at driving
the future value of the business. I trust our customers, partners and investors
are as inspired as us about embarking on a new chapter in the company's
history."

-ENDS-

For more information, please contact:

ArcticZymes
Technologies
Jethro        Tel: +47 46 85 91 46Email: Jethro.holter@arcticzymes.com
Holter, CEO
Børge         Tel: +47 95 29 01 87Email: borge.sorvoll@arcticzymes.com
Sørvoll, CFO

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on premium
and novel enzyme as well as immunomodulating beta-glucan technology.

The ArcticZymes Technologies Group is creating value from innovation in life
science markets via its subsidiaries, ArcticZymes and Biotec BetaGlucans. Its
technologies capitalize on more than three decades of world-class research at
the Arctic University of Tromsø to offer niche and high-tech products in several
biotech segments.

ArcticZymes represents its core business where it develops, manufactures and
commercializes novel recombinant enzymes for use in molecular research, In Vitro
Diagnostics (IVD) and therapeutics.

Biotec BetaGlucans represents a non-core business where it produces and markets
immunomodulating beta-glucans addressing several market areas.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' unique IP and capabilities are protected via a large
portfolio of patents around both enzyme and beta-glucan products.

For more information, please visit the website: www.arcticzymes.com.